Product imageResearch use only

CAT. NO. DC80065Featured

113-O12B

Research highlights

Lymph-node-targeted mRNA delivery after subcutaneous administrationOptimized component weight ratio 16:4.8:3:2.4 (active lipid:cholesterol:helper lipid:DMG-PEG)Higher antigen-presenting-cell transfection than ALC-0315 in the reported mouse studyTRP2 mRNA vaccine plus anti-PD-1 produced a 40% complete-response rate in the regular B16F10 model

Pack size & price

USD

Total$480

We match the best price and quality on market.

Ships from ShanghaiIce-pack transportPure lipid recommended

Product overview

Description & Application

113-O12B LNP, an LN-targeting LNP delivery system, is developed for a mRNA cancer vaccine.

CAS No.	Not available
Chemical Name	113-O12B
Synonyms	113O12B， 113 O12B
SMILES	N(CCC(OCCSSCCCCCCCC)=O)(CCC(=O)OCCSSCCCCCCCC)CCN(C)CCN(CCC(=O)OCCSSCCCCCCCC)CCC(=O)OCCSSCCCCCCCC
Formula	C57H111N3O8S8
M.Wt	1223.03
Purity	>95% by ELSD-HPLC
Storage	Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping condition	Ships from Shanghai. Pure lipid is stable during ice-pack transport.
Publication	Chen J, Ye Z, Huang C, et al. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response. Proc Natl Acad Sci USA. 2022;119:e2207841119.

Literature-reported formulation composition

Component	mol%	Role
113-O12B	Not reported	Ionizable lipid
Cholesterol	Not reported	Sterol
DOPC	Not reported	helper_lipid
DMG-PEG2000	Not reported	PEG lipid
Reported total	Not reported	Source values retained

Formulation calculator unavailable. The supplied article does not report the complete molar composition, so a formulation weight calculation is not available. Obtain and verify the complete composition and component molecular weights before planning component quantities.

N/P ratioNot reported in the cited article

Total lipid:cargo weight ratio10:1 (blank LNP: mRNA mixing ratio, reported in Methods)

Buffer & pH25 mM sodium acetate; pH was not stated in the accessible main text.

CargoLuciferase mRNA, Cre mRNA, OVA mRNA, or TRP2(180-188)-encoding mRNA

Administration routeSubcutaneous injection at the tail base for LN targeting and vaccination; intravenous rechallenge model was used for lung metastasis assessment.

DoseScreening and vaccination doses are stated as active-lipid and mRNA amounts in the cited experiments: OVA studies used 50 µg active lipid + 5 µg OVA mRNA per dose; regular B16F10 TRP2 studies used 30 µg active lipid + 3 µg TRP2 mRNA per dose.

Animal modelAi14 reporter mice; C57BL/6 mice; B16F10-OVA and B16F10 melanoma models.

Formulation processEthanolic active-lipid/Chol/DOPC/DMG-PEG mixture was added dropwise to 25 mM sodium acetate solution and dialyzed with a 3.5 kDa device. LNP was then mixed with mRNA in aqueous solution at a 10:1 blank-LNP:mRNA weight ratio.

Literature-reported performance for the cited formulation

Literature-reportedLN targeting113-O12B showed higher LN and lower liver expression than ALC-0315 after SC dosing; ALC-0315 liver radiance was about fourfold higher than LN radiance, whereas 113-O12B liver signal was 32% of LN signal.mLuc LNP, 6 h after SC injectionPrimary article Fig. 1D-E

Literature-reportedAPC transfectionApproximately 27% of dendritic cells and 34% of macrophages were positive after 113-O12B/mCre, both higher than ALC-0315 in the same experiment.Ai14 mice, 48 h after SC mCrePrimary article Fig. 1F-G

Literature-reportedOVA vaccine protection113-O12B/mOVA vaccination prevented obvious B16F10-OVA tumor growth and prevented apparent lung metastatic nodules in the reported rechallenge experiment.Two vaccinations; 50 µg active lipid + 5 µg mOVA per dosePrimary article Fig. 2

Literature-reportedEstablished B16F10-OVA therapy113-O12B/mOVA prolonged survival; anti-PD-1 combination increased complete response to 2/5 mice in the reported experiment.Established tumor; vaccine days 5 and 12; anti-PD-1 days 7, 11 and 15Primary article Fig. 4

Literature-reportedRegular B16F10/TRP2 therapy113-O12B/mTRP2 plus anti-PD-1 achieved a 40% complete-response rate and surviving complete responders showed no metastatic lung nodules on rechallenge.30 µg active lipid + 3 µg TRP2 mRNA per dosePrimary article Fig. 5 and Discussion

Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.

The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.

Cited literature for this formulation and performance datasetChen J, Ye Z, Huang C, et al. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response. Proc Natl Acad Sci USA. 2022;119:e2207841119.
Formulation and performance source locations are listed with the evidence items above.

PMC full text · DOI

Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

Mass = concentration × volume × molecular weight

MassConcentrationVolumeMolecular weightg/mol

Enter any three values to calculate the fourth.

C₁V₁ = C₂V₂

C₁mMV₁mLC₂mMV₂mL

Enter any three values to calculate the fourth.

Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass	1 mM	5 mM	10 mM
10 mg	8.1764 mL	1.6353 mL	817.64 μL
25 mg	20.4410 mL	4.0882 mL	2.0441 mL
50 mg	40.8821 mL	8.1764 mL	4.0882 mL
100 mg	81.7641 mL	16.3528 mL	8.1764 mL
250 mg	204.4104 mL	40.8821 mL	20.4410 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?

We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.

Pure lipid or solution — which should I choose?

Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.

How should I measure a small amount of oily or viscous lipid?

Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.

Can you support formulation optimization and scale-up?

Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.

113-O12B

Pack size & price

Description & Application

Recommended Products

Lipid H5T5

A28-C6B2

C18 NC-TNP

Lipid TOT-5

YK-TLR-001

A2T2C9 (CP-LC-1465)

DMA4-H228

Lipid te AA3-Dlin

113-AA-C8C14

Lipid 88